Litcius/Paper detail

Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma

Édouard Reizine, Maxime Ronot, Mario Ghosn, Julien Caldéraro, Nora Frulio, Paulette Bioulac‐Sage, Hervé Trillaud, Valérie Vilgrain, Valérie Paradis, Alain Luciani

2020European Radiology30 citationsDOI

Topics & Concepts

MedicineHepatocellular carcinomaHepatocellular adenomaNeuroradiologyInterventional radiologyAdenomaBiomarkerMagnetic resonance imagingRetrospective cohort studyInternal medicineLesionGastroenterologyNuclear medicineRadiologyPathologyNeurologyChemistryPsychiatryBiochemistryHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesGenetic and Kidney Cyst Diseases
Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma | Litcius